Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Hyperuricemia is linked to cardiovascular disease (CVD), with xanthine oxidase (XO) and uric acid (UA) implicated in heart failure (HF) pathogenesis.
• The precise role of XO-induced UA in HF development, particularly concerning oxidative stress and related cardiovascular effects, requires further elucidation.

Purpose of the Study:

• To review the pathophysiologic mechanisms linking hyperuricemia and HF.
• To discuss uric acid-lowering therapies (ULT) targeting XO inhibition for HF management.
• To summarize evidence on ULT in HF and compare the cardiovascular risks of allopurinol and febuxostat.

Main Methods:

• Literature review of pathophysiologic mechanisms.
• Analysis of current evidence on ULT in HF.
• Comparison of cardiovascular risks associated with allopurinol and febuxostat.

Main Results:

• Up-regulated XO activity and increased reactive oxygen species (ROS) production are central to HF pathogenesis in hyperuricemia.
• XO inhibition demonstrates a dual therapeutic effect: lowering serum UA and reducing ROS.
• ULT, particularly XO inhibitors, show promise in managing HF by mitigating oxidative stress, endothelial dysfunction, inflammation, and insulin resistance.

Conclusions:

• XO inhibition is a potential therapeutic strategy for HF patients with hyperuricemia.
• Understanding the mechanisms and comparing ULTs like allopurinol and febuxostat is crucial for clinical practice and CV risk management in HF.